CD44 and hepatocellular carcinoma: As the interaction of PRG4 with its best-known receptor, CD44, that is expressed in most invasive HCC cell lines, is required for PRG4-mediated enhancement of drug effects, the mapping of CD44-binding sites on PRG4 would be a preliminary step to guide the design of specific PRG4-derived bioactive fragments.